A Real-World Evidence Analysis of Associations Among Costs, Quality of Life, and Disease-Severity Indicators of Alzheimer’s Disease in Thailand

Oct 1, 2019, 00:00
10.1016/j.jval.2019.04.1937
https://www.valueinhealthjournal.com/article/S1098-3015(19)32253-3/fulltext
Title : A Real-World Evidence Analysis of Associations Among Costs, Quality of Life, and Disease-Severity Indicators of Alzheimer’s Disease in Thailand
Citation : https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(19)32253-3&doi=10.1016/j.jval.2019.04.1937
First page : 1137
Section Title : ECONOMIC EVALUATION
Open access? : No
Section Order : 1137

Background

Although an increase in the burden of Alzheimer’s disease (AD) is evident worldwide, knowledge of costs and health-related quality of life (HRQOL) associated with AD in low- and middle-income countries is still lacking.

Objectives

This study aimed to collect real-world cost and HRQOL data, and investigate their associations with multiple disease-severity indicators among AD patients in Thailand.

Methods

We recruited AD patients aged ≥60 years accompanied by their caregivers at a university-affiliated tertiary hospital. A one-time structured interview was conducted to collect disease-severity indicators, HRQOL, and caregiving information using standardized tools. The hospital’s database was used to retrieve healthcare resource utilization occurred over 6 months preceding the interview date. Costs were annualized and stratified based on cognitive status. Generalized linear models were employed to evaluate determinants of costs and HRQOL.

Results

Among 148 community-dwelling patients, average annual total societal costs of AD care were $8014 (95% confidence interval [CI]: $7295-$8844) per patient. Total costs of patients with severe stage ($9860; 95% CI: $8785-$11 328) were almost twice as high as those of mild stage ($5524; 95% CI: $4649-$6593). The major cost driver was direct medical costs, particularly those incurred by AD prescriptions. Functional status was the strongest determinant for both total costs and patient’s HRQOL (P value .001).

Conclusion

Our real-world findings suggest the distinct major cost driver that results from expensive AD treatment, emphasizing the demand of country-specific cost evidence. Increases in cognitive and functional status are significantly associated with decreases in total costs of AD care and improvement in patient’s HRQOL.

Categories :
  • Cost/Cost of Illness/Resource Use Studies
  • Economic Evaluation
  • Mental Health
  • Patient-Centered Research
  • Patient-reported Outcomes & Quality of Life Outcomes
  • Specific Diseases & Conditions
Tags :
  • Alzheimer’s disease
  • costs
  • health-related quality of life
Regions :
ViH Article Tags :